EVERSANA to provide integrated commercialization services, enhancing launch readiness and market entry for differentiated ...
Citius Oncology (CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals (CTXR), announced it has finalized an exclusive agreement with EVERSANA, a provider of global commercialization ...
A simultaneous or sequential combination of brentuximab vedotin and radiotherapy is feasible and well tolerated in patients ...
In a matched analysis involving 110 patients with transformed indolent non-Hodgkin lymphoma (TriNHL) and 391 patients with de ...
The Brighterside of News on MSN
Scientists re-engineer a patient’s own T cells to target and destroy cancer cells
Hodgkin lymphoma and other malignancies that express the CD30 protein have been the scourge of oncologists for decades. For patients whose cancer returns or is treatment-refractory, choices are ...
CHICAGO — In this video, Paolo F. Caimi, MD, MBA, discusses research evaluating whether multi-virus specific T-cells could enhance bispecific antibody activity in lymphoma. Caimi, staff physician at ...
To the Editor: Svoboda et al. (May 8 issue) 1 report on a study of an enhanced chimeric antigen receptor (CAR) T-cell product (huCART19-IL18) in patients with relapsed or refractory lymphoma after ...
CAR-T cells, which are genetically programmed to specifically recognize and kill target cells, have altered the therapeutic landscape of lymphoma. After the tumor antigens are identified by scFv, ...
Learn the signs, symptoms, risk factors, and treatments for Hodgkin lymphoma—plus insights from a doctor who’s also a survivor of the disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback